全文获取类型
收费全文 | 1272篇 |
免费 | 68篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 22篇 |
妇产科学 | 15篇 |
基础医学 | 333篇 |
口腔科学 | 22篇 |
临床医学 | 157篇 |
内科学 | 217篇 |
皮肤病学 | 13篇 |
神经病学 | 123篇 |
特种医学 | 17篇 |
外国民族医学 | 5篇 |
外科学 | 108篇 |
综合类 | 5篇 |
预防医学 | 139篇 |
眼科学 | 11篇 |
药学 | 55篇 |
中国医学 | 1篇 |
肿瘤学 | 83篇 |
出版年
2023年 | 4篇 |
2022年 | 3篇 |
2021年 | 15篇 |
2020年 | 4篇 |
2019年 | 11篇 |
2018年 | 13篇 |
2017年 | 11篇 |
2016年 | 11篇 |
2015年 | 15篇 |
2014年 | 18篇 |
2013年 | 34篇 |
2012年 | 74篇 |
2011年 | 80篇 |
2010年 | 24篇 |
2009年 | 20篇 |
2008年 | 123篇 |
2007年 | 132篇 |
2006年 | 122篇 |
2005年 | 125篇 |
2004年 | 83篇 |
2003年 | 91篇 |
2002年 | 87篇 |
2001年 | 12篇 |
2000年 | 14篇 |
1999年 | 13篇 |
1998年 | 12篇 |
1997年 | 11篇 |
1996年 | 16篇 |
1995年 | 12篇 |
1994年 | 12篇 |
1993年 | 5篇 |
1992年 | 25篇 |
1991年 | 16篇 |
1990年 | 14篇 |
1989年 | 9篇 |
1988年 | 9篇 |
1987年 | 6篇 |
1986年 | 3篇 |
1984年 | 7篇 |
1982年 | 3篇 |
1981年 | 5篇 |
1980年 | 4篇 |
1972年 | 2篇 |
1964年 | 2篇 |
1962年 | 2篇 |
1961年 | 2篇 |
1926年 | 3篇 |
1925年 | 7篇 |
1924年 | 3篇 |
1912年 | 3篇 |
排序方式: 共有1346条查询结果,搜索用时 0 毫秒
11.
12.
13.
14.
Tomas Norlander Sam-Hyun Kwon Gert Henriksson Karl Magnus Westrin Karin Sandstedt Pontus Stierna 《The Laryngoscope》1998,108(3):411-417
To investigate possible effects of corticosteroids on polyp formation and local bacterial colonization, pneumococcal sinusitis was experimentally induced in rabbits pretreated with betamethasone or saline. After 7 days, macroscopic polyps were counted post-mortem and on histologic slides after serial sectioning. Histologic sections were also examined with light microscopy. Macroscopic polyps were significantly fewer in animals given betamethasone, while there was no difference regarding the number of microscopic polyps. Ingrowth of pathogenic microorganisms was found in five of eight rabbits given placebo but in none of the animals treated with corticosteroids (P < 0.05). The reduced number of pathogenic strains in these animals may be explained by a better-preserved local host defense. The lower number of macroscopic polyps in the same animals could be because of a delayed mucosal repair and subsequent polyp formation. 相似文献
15.
Ludvig Paul Muren Asa Karlsdottir Yngve Kvinnsland Tore Wentzel-Larsen Olav Dahl 《Radiotherapy and oncology》2005,75(3):293-302
BACKGROUND AND PURPOSE: To study the impact of the new ICRU 62 'Planning organ at Risk Volume' (PRV) concept on the relationship between rectum dose-volume histogram (DVH) data and toxicity. PATIENTS AND METHODS: The acute gastro-intestinal (GI) RTOG toxicity in 127 prostate cancer patients prescribed a total dose of 70 Gy with conformal irradiation to either the prostate, the prostate and seminal vesicles or the whole pelvis (initial 50 Gy only) were analysed. DVHs were derived for the rectum only and for rectum extended with six PRV margin sets (narrow/intermediate/wide; anterior/anterior and posterior). The data was analysed using permutation tests, logistic regression and effective uniform dose (EUD) calculations. RESULTS: Acute Grade 2 GI toxicity was seen in 22 of 127 cases (17%). Permutation tests showed that the difference between DVHs for patients with and without Grade 2 effects was significant, both for rectum only and rectum PRVs (P-value range: 0.02-0.04), with generally lower P-values for the PRVs. In the logistic regression, the fractional DVH variables (i.e. volumes) were significantly related to toxicity, with approximately 2-3 times as many significant dose levels for the PRVs as for rectum only. E.g. with wide anterior and posterior margins (16 and 11 mm, respectively) the relation was significant at 26 different dose levels (6-7, 13-14, 35-43, 60-71 and 73 Gy), compared to nine levels (38-40, 43-44 and 71-74 Gy) for rectum only. EUDs were significantly different for patients with and without Grade 2 effects both for rectum only and the PRVs (95% confidence interval for EUD increase with Grade 2 effects: 0.1-3.1 Gy). CONCLUSIONS: All statistical methods applied indicated a small, but definite difference in DVH parameters between patients with versus those without Grade 2 effects. The difference was most pronounced when margins of 16 mm anterior and 11 mm posterior were applied. 相似文献
16.
OBJECTIVES: COPD is a common and disabling disease that entails high costs for society. The objectives of this study were to measure the societal costs of COPD in Sweden, and to examine the relationship between severity of illness and costs. METHODS: The costs of COPD were examined using a well-defined and representative cohort of subjects with mild, moderate, and severe COPD. Regular telephone interviews regarding resource utilization were made to a cohort of 212 subjects with COPD derived from studies of the general population in Northern Sweden. RESULTS: The annual per capita cost for COPD in Swedish crowns (SEK) was estimated at SEK 13,418 (1,284 US dollars (USD); 1,448 euros (EUR). The direct and indirect costs were SEK 5,592 (42%) and SEK 7,828 (58%), respectively. A highly significant relationship was found between severity of disease and costs. Costs for severe disease were 3 times as high as costs for moderate disease and > 10 times as high as for mild disease. Large individual variations in the level of costs were found. CONCLUSION: Assuming that the prevalence and treatment patterns are representative of Sweden as a whole, the total costs of COPD to society in 1999 were estimated at SEK 9.1 billion (USD 871 million; EUR 982 million). Subjects with mild disease (83%) accounted for 29%, while subjects with moderate disease (13%) accounted for 41% of the total costs. The subjects with severe disease (4%) accounted for the remainder (30%). Prevention, early diagnosis, and postponement of disease progression should have large monetary and policy implications. 相似文献
17.
Nazanin Zounemat Kermani Mansoor Saqi Paul Agapow Stelios Pavlidis Chihhsi Kuo Kai Sen Tan Sharon Mumby Kai Sun Matthew Loza Frederic Baribaud Ana R. Sousa John Riley Asa M. Wheelock Craig E. Wheelock Bertrand De Meulder Jim Schofield Stephany Sánchez-Ovando Jodie Louise Simpson Katherine Joanne Baines Peter A. Wark Charles Auffray Sven-Erik Dahlen Peter J. Sterk Ratko Djukanovic Ian M. Adcock Yi-ke Guo Kian Fan Chung U-BIOPRED Project Team 《Allergy》2021,76(1):380-383
18.
Rosemary V. Swanson John Adamson Chivonne Moodley Bongani Ngcobo Nicole C. Ammerman Afton Dorasamy Sashen Moodley Zinhle Mgaga Asa Tapley Linda A. Bester Sanil Singh Jacques H. Grosset Deepak V. Almeida 《Antimicrobial agents and chemotherapy》2015,59(6):3042-3051
The antileprosy drug clofazimine has shown potential for shortening tuberculosis treatment; however, the current dosing of the drug is not evidence based, and the optimal dosing is unknown. Our objective was to conduct a preclinical evaluation of the pharmacokinetics and pharmacodynamics of clofazimine in the mouse model of tuberculosis, with the goal of providing useful information on dosing for future studies. Pharmacokinetic parameters were evaluated in infected and uninfected BALB/c mice. Pharmacodynamic parameters were evaluated in Mycobacterium tuberculosis-infected mice that were treated for 12 weeks with one of six different clofazimine dosing regimens, i.e., doses of 6.25, 12.5, and 25 mg/kg of body weight/day and 3 regimens with loading doses. Clofazimine progressively accumulated in the lungs, livers, and spleens of the mice, reaching levels of greater than 50 μg/g in all tissues by 4 weeks of administration, while serum drug levels remained low at 1 to 2 μg/ml. Elimination of clofazimine was extremely slow, and the half-life was dependent on the duration of drug administration. Clofazimine exhibited dose-dependent tissue and serum concentrations. At any dose, clofazimine did not have bactericidal activity during the first 2 weeks of administration but subsequently demonstrated potent, dose-independent bactericidal activity. The antituberculosis activity of clofazimine was dependent on neither the dose administered nor the drug concentrations in the tissues, suggesting that much lower doses could be effectively used for tuberculosis treatment. 相似文献
19.
20.